London -based Cryogenax Seed Fund has collected € 1.9 million as part of the round round to accelerate its transmitted cooling technology to fight the heat stroke.
The UK Innovation and Science Seed Fund (UKI 2S) has invested $ 495k in Cryoogenex as part of the Future Planet Capital.
Founder and CEO of Cryoogenex, Matt AndersonConnected: “Heatstroke is not simply a isolated risk; This is a growing global threat – and existing solutions are not practical enough to address the challenge. We have designed CGX 1 as a defibriller for heatstroke, providing the frontline responsive and military personnel’s ability to effectively treat the heat-related illness, wherever it hurts.
“The support from the UKI2S is important – it not only validates our mission but also provides to accelerate our regulatory exemption, accelerate scale production, and to get this life -saving technology in the hands of those who are most needed.“
Established in 2021, Croezenx heatingstrokes and thermal-related illnesses develop portable on-demand cooling devices designed for rapid treatment on the field. Their flagship products, CGX 1, can be placed in distant, industrial, military and emergency reactions settings by eliminating the need for cold-chain logistics.
The company is targeting the global market throughout the defense, industrial and climate adaptation sector.
CGEX 1, designed to provide fast, life-saving treatment for heatstrokes and thermal-related illnesses-all without the need for ice, refrigeration or complex cold-chain logistics. As described in a ”Heat“, The lightweight device can be deployed within minutes, it creates a potential game-manager for military, industrial and emergency reactions where high temperature life and operations risk.
“This is that in our defense and security investment we notice that kind of innovation“Said Alex LeeInvestment Director in UKI 2S managed by Future Planet Capital. “Croezenax is addressing a critical, global challenge with a solution that we are likely to convert how heat injuries across the sector. We are proud to support them as they scale their effects and set a new criterion for operational protection and elasticity.“
Cryoogenex has been concentrated on dual-usage applications with strong relevance for defense customers such as the UK Defense Ministry (MOD) and the US Defense Department (DOD), where Croezenax says that lots of heat illness is an endless and expensive problem. The company is focusing on rapid expansion in the civilian sector, including energy, construction, mining, emergency services and sports.
Fund will be used to run FDA exemption, production scale up and expand international sales. Croezenax is also developing a light, modular version of its technology and is planning a subscription-based model to create long-term earnings.
By 2030, 700 million people are likely to come into contact with extreme heat, resulting in the loss of productivity at the top of $ 2 trillion annually. The body temperature over 39 degrees centigrade can be severe and even sub-marital heat reduces physical and cognitive performance-according to data provided by Croezenax.
Four environmental causes – temperature, humidity, bright heat and wind speed – combine to push workers to push workers’ safe limits as per the study of the National Institute for Official Safety and Health (NIOSH). Once the body temperature rises above 38 degrees centigrade, the fatigue of heat is set; At 40.6 degrees centigrade, the failure of the limb from the heatstroke and the risk of death increases dramatically.
Climate-powered heat pressure at a time when one of the most urgent global health and economic challenges is derived from the innovation of Cryzenex by providing a scaleable, portable solution to this head-on.
[publish_date
